Ubs Asset Management Americas Inc Lexicon Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 353,508 shares of LXRX stock, worth $127,262. This represents 0.0% of its overall portfolio holdings.
Number of Shares
353,508
Previous 120,387
193.64%
Holding current value
$127,262
Previous $189,000
38.1%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding LXRX
# of Institutions
133Shares Held
245MCall Options Held
52KPut Options Held
178K-
Artal Group S.A. Luxembourg, N4136MShares$49 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$14 Million1.27% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$3.56 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.88MShares$3.56 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.99MShares$3.24 Million0.02% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $67.9M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...